STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx

MAP Verified Summary — reported by STAT News

Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.

This story was scored across MAP’s five-signal verification framework — Context, Presentation, References, Visibility, and Comparison — as part of Media Alert Press’s independent media credibility index. Read the full original story at STAT News →